Background It is now a decade since the World Trade Organization (WTO) adopted the “Declaration
on the TRIPS Agreement and Public Health” at its 4th Ministerial Conference in Doha…

For thirty-five years the Orphan Drug Act of 1983 has provided incentives for pharmaceutical
manufacturers to develop drugs to treat rare diseases—conditions that affect fewer than …

Background Not all new drug products are truly new. Some are the result of marginal innovation
and incremental patenting of existing products, but in such a way that confers no major …

Background Drug repurposing (ie, finding novel uses for existing drugs) is essential for
maximizing medicines’ therapeutic utility, but obtaining regulatory approval for new indications is …

Inhalers are the mainstay of treatment for asthma and chronic obstructive pulmonary disease
(COPD). These products face limited generic competition in the US and remain expensive. …

Background: In March 2020, the Government of Canada introduced measures to reduce
intensifying shortages of prescription drugs during the beginning of the COVID-19 pandemic. …

The large number of biologic drug patents in the United States has contributed to delays in
biosimilar availability.

3. Regalado, A. More than 26 million people have taken an at-home ancestry test. MIT
Technology Review https://www. technologyreview. com/s/612880/more-than-26-million-…

Background Insulin is the primary treatment for type 1 and some type 2 diabetes but remains
costly in the United States, even though it was discovered more than a century ago. High …

Background This review was commissioned to generate broad discussion about how to select
intervention delivery modes when designing a complex, preventive intervention aimed at …